Text
Bigger text
Line height
Text align
Readable font
Visual
Contrast
Grayscale
Hide images
Pause animations
Orientation
Screen reader
Highlight links
Reading mask
Outline focus
Sitemap
Page structure
Marketed as a natural herbal supplement, kratom acts on the same opioid receptors as morphine and heroin. Here’s what research shows, what law enforcement has documented, and what our family learned after losing Cade to kratom—information rarely explained and especially when these products are sold.
Kratom is a plant from Southeast Asia. In the United States, it is sold openly in gas stations, smoke shops, vape stores, and online. Kratom is prohibited for U.S. military personnel, including the Coast Guard. No prescription is required, there is no FDA approval for kratom products, labeling is not standardized, and age restrictions vary by state.
Tree native to Southeast Asia. Products derived from the tree's leaves contain intoxicating chemicals: mitragynineand 7-OH.
Psychoactive ingredient in kratom plant.
Attaches to opioid receptors causing confusion, slowed breathing or other dangerous side effects.
Psychoactive ingredient in kratom plant 13 times stronger than morphine.
Sold as manufactured concentrate with no safety standards or regulations.
Source: RiverStone Health. Last reviewed: September 25, 2026.
Kratom's active compounds — mitragynine and 7-hydroxymitragynine (7-OH) — attach to the same receptors in the brain targeted by opioids like morphine, heroin, and fentanyl. Researchers describe them as "atypical opioids" because they activate the same brain pathways associated with dependence, withdrawal, respiratory depression, and fatal drug interactions.
Your body also produces 7-OH after consuming kratom, meaning the product becomes more potent inside the body, not less. Some commercial products have also been found to contain additional 7-OH added during manufacturing, up to 500% above natural levels, according to Florida Department of Law Enforcement intelligence reporting. 7-OH has been estimated to be up to 13 times more potent than morphine.
The U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) have both identified significant safety concerns associated with kratom.
The FDA warns consumers not to use kratom because of the potential for serious adverse events, including liver toxicity, seizures, and substance use disorder. The FDA has also documented cases in which people experienced tolerance, cravings, continued use despite harmful consequences, and withdrawal symptoms after stopping kratom.
The DEA's Kratom Drug Fact Sheet reports that kratom can produce stimulant effects at lower doses and sedative effects at higher doses. Reported effects include nausea, vomiting, sweating, itching, dry mouth, constipation, increased urination, rapid heart rate, drowsiness, loss of appetite, insomnia, weight loss, liver toxicity, seizures, and hallucinations. DEA also reports cases involving psychotic symptoms, including hallucinations, delusions, and confusion.
These warnings are important because kratom products can vary considerably in their composition, concentration, and formulation. A product sold as a kratom powder, capsule, extract, shot, or other preparation may not have the same concentration of active compounds as another product.
Kratom contains many naturally occurring alkaloids, including mitragynine and 7-hydroxymitragynine (7-OH).
According to the FDA, 7-OH occurs naturally in kratom leaves but is only a minor constituent, accounting for less than 2% of the total alkaloid content of natural kratom leaves. However, FDA reports that 7-OH has substantially greater activity at mu-opioid receptors than mitragynine, kratom's primary alkaloid, as well as greater activity than classical opioids such as morphine.
This distinction matters because products marketed as concentrated or enhanced 7-OH products should not automatically be viewed as equivalent to traditional kratom leaf.
The FDA has specifically raised concerns about products containing concentrated 7-OH and has taken regulatory and enforcement actions involving products marketed as 7-OH. Consumers should be especially cautious about products that are marketed as highly concentrated, enhanced, or unusually potent forms of kratom.
The risks associated with kratom are not limited to the plant's naturally occurring compounds.
The FDA has warned consumers about certain kratom products that were contaminated with Salmonella and/or concerning levels of heavy metals. According to the FDA, these contaminants have resulted in documented illnesses and can create additional health risks for consumers.
This is particularly important because kratom products are sold in many different forms and through a variety of retail and online channels. Consumers may have difficulty determining exactly what is contained in a particular product or whether its ingredients and concentrations have been independently verified.
A product's packaging, labeling, or claim that it is "natural" does not by itself establish that the product is safe.
"Natural"does not mean safe.
"Legal"does not mean approved.
"Supplement"does not mean tested.
This is not a fringe concern.The data below comes from poison control centers, peer-reviewed research, and medical examiner reports, all publicly available and independently verified.
Sources: CDC, “Increases in Kratom-Related Reports to Poison Centers,” MMWR, March 26, 2026, covering 2015–2025. The 6,500% increase and the 1 in 7 and 1 in 16 hospitalization figures come from a separate study: Comstock et al., Addiction, 2026, covering 2010–2023.
Hundreds of deaths in Florida have been linked to kratom. Because kratom is not routinely tested for in medical facilities, the true number may be higher. The CDC, FDA, DEA, and NIH have all raised serious concerns.
The U.S. Navy and Marine Corps have banned kratom use across all personnel.
"Kratom-related adverse effects are increasing in number and complexity in the United States."
Some argue that kratom fills a void, helping people manage pain or ease opioid withdrawal. That conversation exists, and it matters. But it has consistently obscured another conversation: WHAT HAPPENS TO EVERYONE ELSE? They should matter too!
Many consumers have no history of opioid use. They are not seeking addiction treatment. They are students, young adults, and people managing everyday stress, buying something from a shelf because it was presented as natural, legal, and available. They had no way to know it acted on the same brain receptors as heroin or morphine.
Florida’s current rule does not ban all natural kratom leaf. Emergency Rule 2ER26-2, effective August 18, 2026, places certain kratom-related compounds in Schedule I and applies to 7-hydroxymitragynine (7-OH) above specified concentration thresholds, as well as certain related compounds. The rule is currently scheduled to expire June 30, 2027, unless it is replaced, extended, or otherwise addressed by law. Consumers should not assume that a product is unrestricted simply because it is labeled “kratom.”
Source: Florida Emergency Rule 2ER26-2
A peer-reviewed study published in the journal Addiction examined 8,919 kratom exposures reported to US poison centers over 14 years. States with Kratom Consumer Protection Acts showed no meaningful reduction in poisonings, severe outcomes, or hospital use compared to states with no regulation at all. States with outright bans had substantially lower rates of exposures and serious harm.
Kratom is being distributed as free samples at events, slipped into online orders, and stacked at gas station counters. That is not education. That is recruitment. It mirrors the same tactics used to create addiction for profit throughout history.
Regulation without restriction did not work. The data says so.
For Parents & Families
Products are not always clearly labeled, so it can be impossible to know how much 7-OH or mitragynine is in a package. These are the names and warning signs to look for.
If you cannot tell what is in a product and how much, treat it as unknown — and risky.
Kratom's primary compound mitragynine converts in the body to 7-hydroxymitragynine (7-OH), which binds to mu-opioid receptors — the same receptors activated by morphine and heroin — causing respiratory depression that can be fatal.
The Florida Department of Law Enforcement reports that 7-OH is 13 times more potent than morphine. Some enhanced products contain up to 500% more 7-OH than would naturally occur — yet are sold with no warnings.
Independent testing of 20 consumer kratom products found extreme variation in strength. At least one product was compared to "legal morphine" by University of Florida scientists. Consumers have no way to know what they are truly taking.
Kratom has been linked to hundreds of deaths in Florida. Because it is not routinely tested for at autopsy, the true number of fatalities may be significantly underreported. Cade is one of those lives.
Sold in gummies, flavored shots, and ice cream cones, kratom products are designed to appeal to younger consumers. Kratom is widely available in stores frequented by teenagers and young adults with no age verification required.
Reported effects include nausea, hallucinations, tremors, confusion, seizures, difficulty breathing, and psychosis. In one study of poison center data from 2010 to 2023, kratom calls rose 6,500% — from 19 cases to 1,242. Separate CDC data covering 2015 to 2025 records 14,449 total exposure cases, including 3,434 in 2025 alone, a record high.
All data and claims on this website are sourced from peer-reviewed research, government agencies, medical examiner reports, and credible journalism. Sources listed below.